Should FDA Clearance and Supply Chain Risks Drive a Reassessment of Baxter International’s (BAX) Digital Health Strategy?

• Baxter International recently launched the Welch Allyn Connex 360 Vital Signs Monitor in the U.S., featuring advanced connectivity, enhanced security, and customizable clinical workflows following FDA 510(k) clearance.
• The device’s easy upgradability and integration within Baxter’s expanded monitoring portfolio reflect ongoing investment in digital healthcare solutions amid increasing demand for connected patient care technology.
• We’ll explore how the government’s national security investigation into medical device imports could alter Baxter’s investment outlook, particularly considering supply chain risk.

Find companies with promising cash flow potential yet trading below their fair value.

Baxter International Investment Narrative Recap

Owning Baxter International means believing in the company’s potential to drive growth through medical technology innovation, even as it faces persistent margin pressure and volume recovery challenges. The recent U.S. government investigation into medical device imports introduces new supply chain uncertainty and potential tariff risk, but it does not materially change the biggest short-term catalyst: a return to higher hospital utilization and normalization of IV product demand.

Baxter’s launch of the Welch Allyn Connex 360 Vital Signs Monitor is especially relevant in this context, highlighting the company’s focus on digital transformation and their response to the growing demand for connected, secure healthcare devices. This innovation aligns well with the outlook for recovery in hospital purchasing patterns and the push for operational efficiency across health systems.

Yet, in contrast, uncertainty about how supply chain risks from possible tariffs could impact future profitability remains information every investor should…

Read the full narrative on Baxter International (it’s free!)

Baxter International is projected to generate $12.1 billion in revenue and $913.6 million in earnings by 2028. This outlook assumes a 3.7% annual revenue growth rate and a $1.16 billion increase in earnings from the current level of -$247.0 million.

Uncover how Baxter International’s forecasts yield a $29.00 fair value, a 32% upside to its current price.

Exploring Other Perspectives

Six individual fair value estimates for Baxter International from the Simply Wall St Community span from as low as US$19 to over US$20,500. While the catalyst for hospital volume recovery is top of mind, opinions differ on what this could mean for the company’s long-term upside, be sure to compare multiple perspectives.

Explore 6 other fair value estimates on Baxter International – why the stock might be a potential multi-bagger!

Build Your Own Baxter International Narrative

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

No Opportunity In Baxter International?

Right now could be the best entry point. These picks are fresh from our daily scans. Don’t delay:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com